Monthly run archive / October 2026
Modern Formula NASDAQ-Only Top 40
October 4, 2026 research cycle. Model entry: October 5, 2026 close.
This October research version is being archived after the model entry date. The NASDAQ workbook includes October 6 research review notes, after model entry. Results are a retrospective model comparison, not evidence of a portfolio published before entry. The run date labels the research cycle; the actual public timestamp is the hosting deployment record.
First worksheet; original rank order.
The NASDAQ universe
The same process, a different eligible universe.
This portfolio applies the same screen, technical overlay, ranking, and allocation rules to NASDAQ-listed companies. The hypothesis is that technology adoption and AI-enabled productivity may improve earnings across this universe. Persistent outperformance remains a question for the accumulating record.
NASDAQ-listed does not mean technology-only. ONEQ provides the broader NASDAQ Composite comparison across company sizes.
Model performance
Portfolio and benchmark.
Portfolio closes: October 5, 2026. Benchmark close: October 5, 2026.
- Weighted portfolio return
- 0.00%
- ONEQ return
- 0.00%
- Difference vs. ONEQ
- +0.00 pp
Price returns from the entry close, before dividends, fees, and taxes. Splits and other corporate actions require review. Each portfolio is tracked separately; overlapping holdings are not combined into a single track record.
Top-40 model portfolio
Holdings and entry prices.
Per our target weighting, this run uses the top 40 ranked names and applies rank-weighted model allocations. Ranks 1-12, their prices and individual returns, and exact allocations are reserved for members.
Membership access Download public entry snapshot CSV
40 of 40 entry prices recorded. Latest portfolio closes: October 5, 2026.
| Rank | Ticker | Tier | Allocation | Entry date | Entry price | Latest close | Price return |
|---|---|---|---|---|---|---|---|
| 1 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 2 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 3 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 4 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 5 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 6 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 7 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 8 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 9 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 10 | Subscriber Only | Core overweight | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 11 | Subscriber Only | Core | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 12 | Subscriber Only | Core | Member Only | October 5, 2026 close | Member Only | Member Only | Member Only |
| 13 | KDP | Core | Member Only | October 5, 2026 close | $30.89 | $30.89 | 0.00% |
| 14 | NBIX | Core | Member Only | October 5, 2026 close | $144.21 | $144.21 | 0.00% |
| 15 | HRMY | Core | Member Only | October 5, 2026 close | $39.92 | $39.92 | 0.00% |
| 16 | SAIC | Core | Member Only | October 5, 2026 close | $126.90 | $126.90 | 0.00% |
| 17 | VRTX | Core | Member Only | October 5, 2026 close | $503.50 | $503.50 | 0.00% |
| 18 | NTAP | Core | Member Only | October 5, 2026 close | $223.77 | $223.77 | 0.00% |
| 19 | DBX | Core | Member Only | October 5, 2026 close | $34.37 | $34.37 | 0.00% |
| 20 | MEDP | Core | Member Only | October 5, 2026 close | $620.51 | $620.51 | 0.00% |
| 21 | OSPN | Standard | Member Only | October 5, 2026 close | $18.42 | $18.42 | 0.00% |
| 22 | QCOM | Standard | Member Only | October 5, 2026 close | $180.79 | $180.79 | 0.00% |
| 23 | URBN | Standard | Member Only | October 5, 2026 close | $81.60 | $81.60 | 0.00% |
| 24 | COKE | Standard | Member Only | October 5, 2026 close | $194.26 | $194.26 | 0.00% |
| 25 | IPAR | Standard | Member Only | October 5, 2026 close | $113.76 | $113.76 | 0.00% |
| 26 | LECO | Standard | Member Only | October 5, 2026 close | $274.94 | $274.94 | 0.00% |
| 27 | NSIT | Standard | Member Only | October 5, 2026 close | $159.39 | $159.39 | 0.00% |
| 28 | TILE | Standard | Member Only | October 5, 2026 close | $34.86 | $34.86 | 0.00% |
| 29 | UTMD | Standard | Member Only | October 5, 2026 close | $73.31 | $73.31 | 0.00% |
| 30 | VRSN | Standard | Member Only | October 5, 2026 close | $292.26 | $292.26 | 0.00% |
| 31 | ADEA | Starter | Member Only | October 5, 2026 close | $26.07 | $26.07 | 0.00% |
| 32 | CHCI | Starter | Member Only | October 5, 2026 close | $19.17 | $19.17 | 0.00% |
| 33 | HLIT | Starter | Member Only | October 5, 2026 close | $11.22 | $11.22 | 0.00% |
| 34 | JAZZ | Starter | Member Only | October 5, 2026 close | $236.04 | $236.04 | 0.00% |
| 35 | NDSN | Starter | Member Only | October 5, 2026 close | $334.43 | $334.43 | 0.00% |
| 36 | OSW | Starter | Member Only | October 5, 2026 close | $22.92 | $22.92 | 0.00% |
| 37 | DLO | Starter | Member Only | October 5, 2026 close | $14.52 | $14.52 | 0.00% |
| 38 | IBEX | Starter | Member Only | October 5, 2026 close | $43.33 | $43.33 | 0.00% |
| 39 | INCY | Starter | Member Only | October 5, 2026 close | $114.13 | $114.13 | 0.00% |
| 40 | LAUR | Starter | Member Only | October 5, 2026 close | $38.51 | $38.51 | 0.00% |
Opportunity notes
Why the top 15 ranked here.
The score measures fit with the opportunity framework, not a forecast of future returns. Commentary summarizes the supplied October research version. Notes for ranks 1-12 are reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
Subscriber Only
Detailed opportunity note reserved for members.
KDP
Keurig Dr Pepper's enlarged beverage and coffee portfolio and planned separation create a sum-of-the-parts opportunity. The potential value comes from established brands and a simpler corporate structure, not merely a low historical earnings multiple. Acquisition debt, separation costs, and weaker U.S. coffee profitability must be deducted from the upside case.
NBIX
Neurocrine's growing commercial revenue and broader product base support an operating-business valuation. The Soleno acquisition adds VYKAT XR but also uses capital that can no longer be counted as surplus cash. Product concentration, recurring research costs, stock compensation, and the price paid for growth limit the score.
HRMY
Harmony's growing WAKIX franchise produces meaningful profits at a modest operating valuation. Development projects provide potential upside, but the existing product must support the core value case. Higher royalty costs, single-product concentration, and finite exclusivity limit the earnings stream that should be capitalized.
Show ranked research
| Rank | Ticker | Score | Band | Opportunity and risk |
|---|---|---|---|---|
| 1 | Subscriber Only | 83.5 | Strong MF fit | Detailed thesis reserved for members. |
| 2 | Subscriber Only | 78 | Good candidate with hair | Detailed thesis reserved for members. |
| 3 | Subscriber Only | 75 | Good candidate with hair | Detailed thesis reserved for members. |
| 4 | Subscriber Only | 74.5 | Good candidate with hair | Detailed thesis reserved for members. |
| 5 | Subscriber Only | 73 | Good candidate with hair | Detailed thesis reserved for members. |
| 6 | Subscriber Only | 73 | Good candidate with hair | Detailed thesis reserved for members. |
| 7 | Subscriber Only | 72.5 | Good candidate with hair | Detailed thesis reserved for members. |
| 8 | Subscriber Only | 72 | Good candidate with hair | Detailed thesis reserved for members. |
| 9 | Subscriber Only | 71.5 | Good candidate with hair | Detailed thesis reserved for members. |
| 10 | Subscriber Only | 71.5 | Good candidate with hair | Detailed thesis reserved for members. |
| 11 | Subscriber Only | 70 | Good candidate with hair | Detailed thesis reserved for members. |
| 12 | Subscriber Only | 69 | Interesting but messy | Detailed thesis reserved for members. |
| 13 | KDP | 69 | Interesting but messy | Keurig Dr Pepper's enlarged beverage and coffee portfolio and planned separation create a sum-of-the-parts opportunity. The potential value comes from established brands and a simpler corporate structure, not merely a low historical earnings multiple. Acquisition debt, separation costs, and weaker U.S. coffee profitability must be deducted from the upside case. |
| 14 | NBIX | 69 | Interesting but messy | Neurocrine's growing commercial revenue and broader product base support an operating-business valuation. The Soleno acquisition adds VYKAT XR but also uses capital that can no longer be counted as surplus cash. Product concentration, recurring research costs, stock compensation, and the price paid for growth limit the score. |
| 15 | HRMY | 68.5 | Interesting but messy | Harmony's growing WAKIX franchise produces meaningful profits at a modest operating valuation. Development projects provide potential upside, but the existing product must support the core value case. Higher royalty costs, single-product concentration, and finite exclusivity limit the earnings stream that should be capitalized. |
| 16 | SAIC | 68.5 | Interesting but messy | SAIC's contracted federal services, stronger operating results, and raised guidance support its cash-generation case. The backlog and capital returns provide a basis for value without assuming every contract earns the same margin. Budget timing, recompetes, integration, and leverage remain the main limits on normalized earnings. |
| 17 | VRTX | 68.5 | Interesting but messy | Vertex's cystic-fibrosis franchise and revenue growth support high business quality. Acquisition cash outflows and recurring development spending remain real costs even when accounting charges are normalized, and future peak pipeline sales should not be counted as current earnings. |
| 18 | NTAP | 68 | Interesting but messy | NetApp's all-flash and cloud demand, strong quarterly growth, and higher guidance support improved earnings power. The valuation already recognizes considerable progress, while cash conversion, infrastructure cycles, and competition limit the remaining margin of safety. |
| 19 | DBX | 67.5 | Interesting but messy | Dropbox's installed subscription base generates cash and supports repurchases, with new products offering potential upside. Slow core growth, competition, debt-funded distributions, and recurring stock compensation limit the case for assuming a broad acceleration in earnings. |
| 20 | MEDP | 67.5 | Interesting but messy | Medpace's clinical-trial services, growing bookings, and financial resources support strong business quality. A demanding operating valuation leaves less room for cancellations, wage pressure, or weaker funding among smaller biopharma customers. |
| 21 | OSPN | 67.5 | Interesting but messy | OneSpan's recurring security software, growing annual recurring revenue, and financial resources support the opportunity. Higher guidance and the Build38 acquisition add potential, but operating income needs to keep pace with adjusted earnings. Legacy hardware decline, acquisition integration, and cash costs temper the apparent discount. |
| 22 | QCOM | 67.5 | Interesting but messy | Qualcomm's licensing franchise and automotive and connected-device growth provide a basis for value during a handset transition. Customer insourcing, acquisition costs, and the valuation constrain upside, even as AI software capabilities broaden the longer-term opportunity. |
| 23 | URBN | 67.5 | Interesting but messy | Urban Outfitters' brands and Nuuly subscriptions support operating growth and a credible cash-earnings case. Tariff refunds must be removed from margins, while fashion demand, inventory, leases, and capital requirements limit the quality premium. |
| 24 | COKE | 66 | Interesting but messy | Coca-Cola Consolidated's bottling territories and distribution scale support recurring demand and cash conversion. Debt, labor and packaging costs, and maintenance capital distinguish its economics from an asset-light brand royalty business. |
| 25 | IPAR | 66 | Interesting but messy | Interparfums' fragrance licenses and distribution network support attractive brand economics. Marketing commitments, logistics costs, launches, minority ownership, and temporary refund benefits require care when estimating cash attributable to common shareholders. |
| 26 | LECO | 66 | Interesting but messy | Lincoln Electric's welding and automation positions support durable operating returns and strong cash conversion. The valuation recognizes much of that quality, with industrial demand, integration, and maintenance investment limiting the remaining discount. |
| 27 | NSIT | 66 | Interesting but messy | Insight Enterprises combines distribution scale with a growing services and cloud mix. Acquisition debt, vendor relationships, and working-capital swings make gross profit and cash after financing needs more informative than hardware pass-through revenue alone. |
| 28 | TILE | 66 | Interesting but messy | Interface's sales growth, backlog, and higher guidance support an operating-improvement case. Tariff refunds should be stripped from reported margin gains, while debt, renovation cycles, and manufacturing costs constrain normalized value. |
| 29 | UTMD | 66 | Interesting but messy | Utah Medical's profitable operations and issuer tender offer provide a concrete capital-return case, despite revenue lost with major customers. The offer described in this research is an issuer repurchase, not a third-party takeover; tender cash, customer concentration, and litigation exposure must be reflected in the valuation. |
| 30 | VRSN | 66 | Interesting but messy | Verisign's domain-registry contracts and pricing provide unusually profitable recurring revenue. A substantial quality premium, net debt, regulation, and domain-volume constraints limit the value gap despite the franchise's durability. |
| 31 | ADEA | 65.5 | Interesting but messy | Adeia's patent licenses produce high-margin cash flow with limited physical capital needs, supported by renewals and semiconductor adoption. Contract timing, litigation costs, debt, and recurring operating expenses limit how much of adjusted earnings can be treated as dependable owner cash. |
| 32 | CHCI | 65.5 | Interesting but messy | Comstock's property-management and development fees support a profitable, capital-light business with cash and no funded debt in the supplied research. Related-party concentration and project timing constrain reliability, while investment gains and tax benefits should be separated from recurring operating earnings. |
| 33 | HLIT | 65.5 | Interesting but messy | Harmonic's broadband growth and stronger guidance support its business following the video divestiture. Concentrated customers and deployment timing create variability, so continuing earnings should be normalized rather than extrapolated from a particularly strong quarter. |
| 34 | JAZZ | 65.5 | Interesting but messy | Jazz's established commercial franchises and raised revenue guidance support real operating cash flow. Debt, acquisitions, product replacement, and necessary research spending limit how directly adjusted earnings translate into owner cash. |
| 35 | NDSN | 65.5 | Interesting but messy | Nordson's precision-dispensing technologies, switching costs, and recurring customer process needs support high business quality. The valuation, acquisition debt, and industrial and semiconductor capital cycles leave a more modest mispricing opportunity. |
| 36 | OSW | 65.5 | Interesting but messy | OneSpaWorld's cruise wellness concessions support capital-light growth without requiring ownership of the vessels. Cruise demand, staffing, concession renewals, revenue sharing, and an already substantial earnings multiple limit the valuation gap. |
| 37 | DLO | 65 | Interesting but messy | dLocal's expanding payments platform and strong balance sheet support its operating value. Falling gross profit relative to payment volume and rising costs make rapid volume growth an incomplete measure of shareholder earnings, with emerging-market exposure adding risk. |
| 38 | IBEX | 65 | Interesting but messy | IBEX combines revenue and earnings growth with cash generation and capital returns. Customer concentration, wage costs, and the potential for AI to replace outsourced service work limit the duration and valuation assigned to current earnings. |
| 39 | INCY | 65 | Interesting but messy | Incyte's Jakafi and Opzelura franchises support recurring commercial cash flow. A noncash reimbursement adjustment and acquired research charges complicate reported results, while patent concentration and pipeline spending remain the main valuation constraints. |
| 40 | LAUR | 65 | Interesting but messy | Laureate's established campuses and recurring enrollment in Mexico and Peru support cash earnings and capital returns. Currency exposure, tuition affordability, and education-sector regulation constrain the durability premium warranted by current growth. |
Benchmarks
Comparison baseline.
| Benchmark | Entry date | Entry price | Status |
|---|---|---|---|
| ONEQ | October 5, 2026 close | $108.34 | Started |
Publication ledger
Research version and record.
- Research cycle
- October 4, 2026
- Entry date
- October 5, 2026 close.
- Latest dated source information
- September 30, 2026
- Publication timing
- Prepared after entry. See the hosting deployment record for the actual public timestamp.
- Source workbook
- Consolidated_Oct-2026_NASDAQ.xlsx
- Source worksheet
- Consolidated
- Ranking CSV SHA-256
cacba9328935c378e2a6134de40a6c157faeeb22d18ac259e711324c700c86ff- Portfolio CSV SHA-256
0afc37f5b9e139a0d5c2f7416855533df174344a832a6e019896f8e22bd9de27- Manifest
- View publication manifest
Preserve the original publication and record any corrections with a new date. Portfolio closes can be updated separately from the archived research.